Sunshine Biopharma Inc. 8-K

What Happened

• On February 18, 2026, Dr. Steve N. Slilaty—Sunshine Biopharma’s chief executive officer and holder of about 96% of the company’s voting power—approved by written consent a proposal authorizing the company’s board of directors to effect a reverse split of the company’s issued and outstanding common stock in a ratio of up to 1-for-10.
• The board has discretion whether to implement the reverse split and to set the exact whole-number ratio (anywhere up to 1-for-10). The shareholder consent becomes effective 20 days after the definitive information statement relating to the consent is mailed to stockholders. The company filed the 8-K on February 20, 2026.

Key Details

• Date of shareholder written consent: February 18, 2026.
• Authorized reverse split ratio: up to 1-for-10 (exact whole-number ratio to be set by the board).
• Effective timing: consent effective 20 days after mailing of the definitive information statement to stockholders.
• Controlling shareholder: Dr. Steve N. Slilaty (CEO) holds ~96% of voting power.

Why It Matters

• A reverse stock split reduces the number of outstanding shares and increases the per-share price, which can affect trading liquidity and market perception of the stock.
• Because the CEO controls roughly 96% of voting power, he effectively determined that the board may pursue a reverse split; minority stockholders have limited ability to block the authorization.
• The board still must decide whether and when to implement the split and at what exact ratio, and the authorization does not itself change share counts until the board acts and the effective date passes.